APC8024: Interim Phase I data

Pooled data from 2 Phase I trials (D2000-1 and D2000-2) in 21 evaluable patients with advanced metastatic HER-2/neu-positive breast cancer showed that 8 weeks of APC8024 induced a significant immune r...